(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(0.38%) $78.41
(0.47%) $2.15
(0.44%) $2 318.80
(1.64%) $27.13
(-0.36%) $961.85
(0.02%) $0.929
(-0.05%) $10.87
(0.00%) $0.797
(0.00%) $91.45
Quarter results tomorrow
(bmo 2024-05-07)
Expected move: +/- 10.31%
2.35% $ 2.61
@ $2.49
Wydano: 13 vas. 2024 @ 22:29
Zwrot: 4.82%
Poprzedni sygnał: vas. 13 - 16:30
Poprzedni sygnał:
Zwrot: 0.81 %
Live Chart Being Loaded With Signals
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration...
Stats | |
---|---|
Dzisiejszy wolumen | 1.34M |
Średni wolumen | 2.26M |
Kapitalizacja rynkowa | 393.16M |
EPS | $0 ( 2024-03-12 ) |
Następna data zysków | ( $-0.0800 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.26 |
ATR14 | $0.00400 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-19 | Duarte Ira | Buy | 3 874 | Common Stock |
2024-04-19 | Duarte Ira | Sell | 1 122 | Common Stock |
2024-04-19 | Duarte Ira | Sell | 3 874 | Restricted Stock Units |
2024-04-19 | Forbes William P | Buy | 3 874 | Common Stock |
2024-04-19 | Forbes William P | Sell | 3 874 | Restricted Stock Units |
INSIDER POWER |
---|
66.44 |
Last 96 transactions |
Buy: 15 032 989 | Sell: 3 241 807 |
Wolumen Korelacja
Heron Therapeutics Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
TTGT | 0.894 |
TFFP | 0.891 |
BMAQ | 0.89 |
BRIVU | 0.889 |
RMRM | 0.888 |
MSDA | 0.885 |
TIOA | 0.884 |
VSTA | 0.884 |
CRWD | 0.884 |
KROS | 0.882 |
10 Najbardziej negatywne korelacje | |
---|---|
TENX | -0.91 |
TVACW | -0.903 |
BOCH | -0.901 |
NETE | -0.9 |
RELL | -0.899 |
VTNR | -0.898 |
FFIE | -0.895 |
AMRB | -0.894 |
AGRI | -0.893 |
CRCT | -0.893 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Heron Therapeutics Inc Korelacja - Waluta/Towar
Heron Therapeutics Inc Finanse
Annual | 2023 |
Przychody: | $127.04M |
Zysk brutto: | $61.94M (48.75 %) |
EPS: | $-0.800 |
FY | 2023 |
Przychody: | $127.04M |
Zysk brutto: | $61.94M (48.75 %) |
EPS: | $-0.800 |
FY | 2022 |
Przychody: | $107.67M |
Zysk brutto: | $52.80M (49.04 %) |
EPS: | $-1.240 |
FY | 2021 |
Przychody: | $87.18M |
Zysk brutto: | $41.16M (47.21 %) |
EPS: | $-2.24 |
Financial Reports:
No articles found.
Heron Therapeutics Inc
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej